Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Trial details
- Registry ID
- NCT03522298
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed GlioblastomaNCT03522298 | Kazia Therapeutics Limited | Phase 2 | Completed | 2023-03-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |